Pluripotent stem cell trial for Huntington’s disease
Early-stage study marks milestone for regenerative medicine
Read More
Author: John Pinching
Jascayd gains UK licence for treatment of pulmonary fibrosis
New option for adults with IPF and PPF
Read More
Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy
SEGRAM aims to offer an alternative to glucocorticoid‑based treatment
Read More
The overlooked burden of ageing
Why the UK needs a unified strategy for chronic disease and adult vaccination
Read More
Compass Pathways reports six‑month data confirming durable profile of COMP360
Second phase 3 trial shows sustained benefit and supports forthcoming regulatory submission
Read More- Pluripotent stem cell trial for Huntington’s disease
- Jascayd gains UK licence for treatment of pulmonary fibrosis
- Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy
- Compass Pathways reports six‑month data confirming durable profile of COMP360
- Ferrer and Prilenia begin confirmatory study of pridopidine in Huntington’s disease
